Literature DB >> 3941804

Cellular pharmacology of doxorubicin in sensitive and resistant rat glioblastoma cells in culture.

P Vrignaud, D Londos-Gagliardi, J Robert.   

Abstract

We have studied the incorporation and cytotoxicity of doxorubicin in cultured rat C6 glioma cells grown as monolayers. Net incorporation was linear up to high extracellular concentrations of drug (10 micrograms/ml). Cytotoxicity was evaluated both by tritiated thymidine incorporation inhibition and cloning efficiency inhibition. For similar total drug exposures, cytotoxicity was very different according to the exposure time and the exposure dose; incubation with a low dose for a long time was much less cytotoxic than that performed with a high dose for a short period of time. We have obtained several clones of doxorubicin-resistant cells. As compared to the wild strain, these cells were characterized by a larger size, a slower growth, a reduced cloning efficiency and a differential sensitivity of 100-1,000 to doxorubicin. Net incorporation of doxorubicin was 5-fold reduced in these cells, due to an increased efflux of the drug. These cells provide an interesting model of doxorubicin-resistant solid tumor in culture.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3941804     DOI: 10.1159/000226106

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  8 in total

1.  A new mathematical pharmacodynamic model of clonogenic cancer cell death by doxorubicin.

Authors:  Jan Lankelma; Rafael Fernández Luque; Henk Dekker; Jaap van den Berg; Bob Kooi
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-07-18       Impact factor: 2.745

2.  Cell cycle checkpoint models for cellular pharmacology of paclitaxel and platinum drugs.

Authors:  Ardith W El-Kareh; Rachel E Labes; Timothy W Secomb
Journal:  AAPS J       Date:  2008-02-05       Impact factor: 4.009

3.  Development of alkylating agent-resistant human tumor cell lines.

Authors:  B A Teicher; E Frei
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

4.  Pharmacokinetics of doxorubicin in sarcoma patients.

Authors:  J Robert; N B Bui; P Vrignaud
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

5.  Two-mechanism peak concentration model for cellular pharmacodynamics of Doxorubicin.

Authors:  Ardith W El-Kareh; Timothy W Secomb
Journal:  Neoplasia       Date:  2005-07       Impact factor: 5.715

6.  Hepatic metabolism of doxorubicin in mice and rats.

Authors:  P Vrignaud; D Londos-Gagliardi; J Robert
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1986 Apr-Jun       Impact factor: 2.441

7.  Cellular pharmacology of 4'-iodo-4'-deoxydoxorubicin.

Authors:  B Schott; P Vrignaud; C Ries; J Robert; D Londos-Gagliardi
Journal:  Br J Cancer       Date:  1990-04       Impact factor: 7.640

8.  Single-cell Western blotting after whole-cell imaging to assess cancer chemotherapeutic response.

Authors:  Chi-Chih Kang; Jung-Ming G Lin; Zhuchen Xu; Sanjay Kumar; Amy E Herr
Journal:  Anal Chem       Date:  2014-10-01       Impact factor: 6.986

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.